Monalizumab

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A) . Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) [1][2].

Product Specifications

CAS Number

[1228763-95-8]

Product Name Alternative

IPH2201

UNSPSC

12352203

Target

Checkpoint Kinase (Chk) ; IFNAR

Type

Inhibitory Antibodies

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/monalizumab.html

Purity

99.93

Solubility

H2O

Smiles

[Monalizumab]

Molecular Weight

(146.3 kDa)

References & Citations

[1]Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7 (1) :263.|[2]Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel) . 2020 Sep 21;12 (9) :2691.|[3]McWilliams EM, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016 Sep 9;5 (10) :e1226720.|[4]Melero I, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. EMBO Mol Med. 2023 Nov 8;15 (11) :e17804.|[5]Maximilian Pinho-Schwermann, et al. Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade.doi https://doi.org/10.1101/2023.11.15.567201